KBI-058 (also identified as Maralixibat) is an investigational drug, primarily recognized as a potent inhibitor of the apical sodium-dependent bile acid transporter (ASBT). By blocking this transporter, the compound prevents the reabsorption of bile acids in the small intestine, significantly increasing their excretion in stool and lowering systemic bile acid levels. Therapeutic Focus and Clinical Applications
Your Challenge for This Week:
In certain liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the liver's ability to manage bile acid circulation is impaired. This can lead to the accumulation of toxic bile acids within liver cells, contributing to liver damage. KBI-058
In the years since its release, KBI-058 has undergone a critical re-evaluation. It is no longer seen as an outlier but rather as a precursor to a wave of "slow cinema" within its specific production category. Directors who have cited KBI-058 as an influence often mention its courage to allow the camera to linger on an actor's face without dialogue, trusting the audience to read the micro-expressions. KBI-058 (also identified as Maralixibat ) is an
His terminal buzzed. An encrypted message from O5 Command. This can lead to the accumulation of toxic
"The asset was recovered," the liaison said. "The mission is a success."